X-ray and mammography equipment vendor Fischer Imaging reported revenue of $19.8 million for the second quarter, ended June 30, 2004, a 64% increase over revenue of $12.1 million for the same period in 2003. Net income for the 2004 second quarter was
X-ray and mammography equipment vendor Fischer Imaging reported revenue of $19.8 million for the second quarter, ended June 30, 2004, a 64% increase over revenue of $12.1 million for the same period in 2003. Net income for the 2004 second quarter was $3.2 million compared with a net loss of $2.4 million in the comparable 2003 period. Results were bolstered, however, by an amended 2002 patent settlement agreement. The amendment provided a one-time payment totaling $4.3 million in lieu of six remaining $0.9 million payments that were due annually through 2010. The gross margin on product sales was 28.5% in the second quarter of 2004, down from 33.1% in the second quarter of 2003. The negative service margin was primarily a result of increased parts usage associated with installed SenoScan systems. The company's quality improvement initiatives and eventual contract maintenance revenue increases are expected to favorably impact both product and service margins over time.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.